🇦🇺Australia
Prescription Access Scheme Delays
2 verified sources
Definition
Delays in SAS or Authorised Prescriber processes for regulated natural therapies result in unbilled services and capacity loss.
Key Findings
- Financial Impact: AUD 1,000-5,000 revenue per delayed treatment (2-4 week approval); 5-10 hours admin per application
- Frequency: Per prescription-only therapy plan
- Root Cause: Manual handling of TGA portal submissions
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Alternative Medicine.
Affected Stakeholders
Doctors, Compliance Officers
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Informed Consent Non-Compliance Fines
AUD 5,000-50,000 penalty per breach (typical range for professional misconduct); 10-20 hours per audit response
Treatment Plan Rework and Refunds
AUD 500-2,000 per refund (average claim); 2-5% revenue loss from repeat issues
TGA Non-Reporting Penalties
AUD 100,000 to 500,000+ civil penalty per serious breach
AEFI Under-Reporting Costs
2-5% annual revenue loss from recalls and claims; 20-40 hours/month manual reporting burden
State AEFI Reporting Fines
AUD 5,000-20,000 fine per unreported statutory AEFI
Verzögerter Geldeingang bei Selbstzahler-Abonnements
Quantified: ≈ 39 % higher receivables without optimised billing; for AUD 100,000 monthly sales this can mean ≈ AUD 39,000 extra outstanding plus ≈ 1–3 % of annual revenue (AUD 12,000–36,000) in bad‑debt write‑offs.